- Launch and Distribution of “MIEr for ImageFS”（PDF）
- Launch of Distribution of Software for Dry-eye Analysis（PDF）
- Acquisition of Marketing Approval for “ Mytear LUMIFY”（PDF）
- Launch of Distribution of RET-700（PDF）
- Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132（PDF）
- Notice of Orphan Drug Designation for SJP-0008 as a Treatment of Central Retinal Artery Occlusion（PDF）
- Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion（PDF）
- Launch and Distribution of “MIEr for NAVIS”（PDF）
- Launch of Distribution of the OptiLight M22 IPL Model（PDF）
- Launch of Distribution of “Smart MIEr”（PDF）
- Senju initiated Phase III Clinical Trials in Japan for “SJP-0132” for the treatment of Dry Eye Disease. The Clinical Trials use a novel compound discovered by Mochida and licensed to Senju（PDF）
- Announcement of collaboration agreement with Alchemedicine, Inc.（PDF）
- Launch of Distribution of “MIEr-Blue” and “MIEr-Red”（PDF）